News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LipidViro Tech, Inc. (LVRO) Release: New Trial Results Support Best-In-Class Heart Failure Treatment


9/7/2006 3:51:55 PM

SALT LAKE CITY, Sept. 6 /PRNewswire-FirstCall/ -- LipidViro Tech, Inc. (OTC Bulletin Board: LPVT - News) comments on Phase III data presented by competitor Vasogen Inc. at the 2006 World Congress of Cardiology, Sept 2-6 Barcelona, Spain. Vasogen and LipidViro Tech are developing competing apoptotic therapies for treating Chronic Heart Failure (CHF). New results from Vasogen's landmark Phase III CHF study reported (1):

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES